Below is a list of the reports in the category you have selected. Click to order the report or download a brochure.

Therapeutic Classes

Document Title: Thought Leader Insight & Analysis -- Anticoagulants Q2 2010 Focus Area: Anticoagulants Specialty/Panel Description: Cardiology, Electrophysiology/N. America, Europe   Publication Date: 05/13/2010   Principal Authors: Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD   Product Code: MCVQ210-9   Pricing: $7,500.00   Abstract: This Cardiovascular Thought Leader Panel reviews the most important anticoagulant data presented at ACC 2010 with six international Thought Leaders who have a stake in anticoagulation therapy. This Panel focuses on the use of antithrombotics and antiplatelets in the prevention of cerebrovascular events associated with acute coronary syndrome (ACS) or secondary prevention of atrial fibrillation (SPAF). Picking up where they left off in our last report, this Panel opines on competitive strengths and weaknesses of marketed products and experimental therapeutics with high likelihood of being commercialized. Panelists differentiate each drug based on clinical trial design, anticoagulant efficacy, increased bleeding risk, convenience, associated therapeutic limitations, costs and genetic screening/diagnostics.   Brochures: Anticoagulants Brochure Q2 2010

Document Title: Thought Leader Insight & Analysis -- Anticoagulants Q1 2010 Focus Area: Anticoagulants Specialty/Panel Description: Cardiologists, Orthopedic Surgery / N. America, Europe   Publication Date: 02/01/2010   Principal Authors: Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD, MBA   Product Code: MCVQ110-8   Pricing: $7,500.00   Abstract: This report is based on interviews with seven Thought Leaders who have a stake in anticoagulation therapy. The discussions took place in January 2010. This Panel continues where our last report left off, exploring the revolutionary use of antithrombotics and antiplatelets for use in the prevention of ischemic events during/after surgery, acute coronary syndrome, secondary prevention venous thromboembolism and secondary prevention for atrial fibrillation. Together, the insights from these interviews can be thought of as a “war-game”, laying out the competitive strengths and weaknesses of marketed products and experimental therapeutics with high likelihood of being commercialized. Panelists differentiate each drug based on clinical trial design, anticoagulant efficacy, increased bleeding risk, convenience, associated therapeutic limitations and costs.   Brochures: Anticoagulants Brochure Q1 2010

Document Title: Thought Leader Insight & Analysis -- Anticoagulants Q3 2009 Focus Area: Anticoagulants Specialty/Panel Description: Cardiologists/N. America, Europe (8)   Publication Date: 09/24/2009   Principal Authors: Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD, MBA   Product Code: MCVQ309-7   Pricing: $7,500.00   Abstract: This report is based on interviews with eight Thought Leaders who have a stake in anticoagulation therapy, conducted immediately after the European Society of Cardiology 2009 meeting. On the antithrombotics front, the news at ESC was dominated by Pradaxa (dabigatran). Our Panel was very favorably impressed by the RE-LY data, but also points out meaningful ways for follow-on antithrombotics to compete in the SPAF (secondary prevention of stroke in patients with atrial fibrillation) market. According to our Panel, it is important to realize that SPAF is undertreated today and there will be plenty of room for follow-up drugs, either direct thrombin inhibitors or anti-FXa. The Panel next turns to platelet inhibition strategies for the treatment of ACS (acute coronary syndrome). In order to clarify their position on the roles of clopidogrel, prasugrel and ticagrelor, they dissect the CURRENT-OASIS-7 and PLATO trials, and make relevant comparisons and contrasts to TRITON.   Brochures: Anticoagulants Brochure Q3 2009

Document Title: Thought Leader Insight & Analysis -- Anticoagulants Q1 2009 Focus Area: Anticoagulants Specialty/Panel Description: Emergency Medicine, Cardiology, Orthopedic Surgery, Electrophysiology/N. America, Europe   Publication Date: 01/27/2009   Principal Authors: Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD, MBA   Product Code: MCVQ109-6   Pricing: $7,500.00   Abstract: This report is based on interviews with six Thought Leaders who have a stake in anticoagulation therapy: two who specialize in emergency medicine, two in cardiology, one in orthopedic surgery and one in electrophysiology. The discussions took place in December 2008. Anticoagulation therapy is being studied in a variety of settings, including elective and non-elective surgery, acute coronary syndrome, prevention and treatment of deep vein thrombosis / pulmonary embolism, secondary prevention of strokes in patients being treated for atrial fibrillation and oncology. Our Thought Leaders share their opinions on antithrombotics and antiplatelets driven by different patient populations and differing therapeutic goals.   Brochures: Anticoagulants Brochure Q1 2009

Document Title: Thought Leader Insight & Analysis -- Antithrombotics, Antiplatelets Q108 Focus Area: Cardiovascular Specialty/Panel Description: Cardiologists / N. America   Publication Date: 01/14/2008   Principal Authors: Tricia L. Hanlon, Kim Grant, Jeffrey D. Berk, PhD, MBA   Product Code: MCVQ108-3   Pricing: $6,000.00   Abstract: This report is based on a series of six new interviews with US Thought Leaders (emergency medicine, cardiothoracic surgery, cardiology), and supporting comments from our last panel. It focuses on unmet needs related to antithrombotic and antiplatelet therapy, and a rather large group of developmental therapies targeting acute, sub-acute and long-term indications for these two classes of drugs. Thromboembolic disease kills more people every year than lung cancer. As an oral antithrombotic, warfarin is the much despised standard of care. Sanofi-Aventis has established enoxaparin as the leading hospital based low molecular weight heparin. In the next two years each will face significant short-term competitive challenges from new orally available direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban). Clopidogrel has dominated the antiplatelet category for a decade. It too has notable limitations that are about to be exploited. See brochure for more.   Brochures: Cardiovascular Brochure Q1 2008